⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1101993 | 0.84 | — | — | |
| SCHEMBL13351812 | 0.79 | — | — | |
| SCHEMBL7364447 | 0.79 | — | — | |
| SCHEMBL840069 | 0.79 | — | — | |
| SCHEMBL1117976 | 0.79 | — | — | |
| SCHEMBL840154 | 0.76 | — | — | |
| SCHEMBL738728 | 0.73 | — | — | |
| SCHEMBL840809 | 0.71 | — | — | |
| SCHEMBL839911 | 0.70 | CYP2D6 (0.31) | — | |
| SCHEMBL4389108 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | AGIOS PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | ALUMIS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| CN-116490165-A | Abiraterone prodrugs | 普洛佩拉治疗公司 | 2023-07-25 | — | — | CN | disclosed |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| CN-114072395-A | Heterocyclic compounds and their use for treating helminth infections and diseases | 新基公司 | 2022-02-18 | — | — | CN | disclosed |
| US-10919885-B2 | Compounds and uses thereof | YUMANITY THERAPEUTICS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190330198-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-31 | — | — | US | disclosed |
| CN-106795157-B | The N- pyridine yl acetamide derivatives of inhibitor as Wnt signal transmission approach | 莱德克斯制药公共有限公司 | 2019-07-23 | — | — | CN | disclosed |
| CN-106795157-A | As the N pyridine yl acetamide derivatives of the inhibitor of Wnt signals transmission approach | 莱德克斯制药公共有限公司 | 2017-05-31 | — | — | CN | disclosed |
| US-9444058-B2 | Preparation of pi-extended naphthalene diimides and their use as semiconductor | BASF SE (DE) | 2016-09-13 | — | — | US | disclosed |
| US-20090105271-A1 | PYRIDYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-23 | — | — | US | disclosed |
| US-20090012117-A1 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-08 | — | — | US | disclosed |
| US-20080119453-A1 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-22 | — | — | US | disclosed |
| US-20080113990-A1 | Biphenyl derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-15 | — | — | US | disclosed |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-31 | — | — | US | disclosed |
| US-20070225499-A1 | Process for the Preparation of 2,2-Disubstituted Pyrroles | MERCK & CO., INC. | 2007-09-27 | — | — | US | disclosed |
| US-20070203130-A1 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
| US-20070203130-A1 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
| US-20070117801-A1 | Indane derivatives as modulator of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-24 | — | — | US | disclosed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | disclosed |